HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.
You may also be interested in...
CLIAC Waiver Criteria Input Readied As FDA Gears Up To Draft Guidance
The Clinical Laboratory Improvement Advisory Committee is close to issuing waiver recommendations, after agreeing to largely adopt criteria developed by its CLIA waiver workgroup
CLIAC Waiver Criteria Input Readied As FDA Gears Up To Draft Guidance
The Clinical Laboratory Improvement Advisory Committee is close to issuing waiver recommendations, after agreeing to largely adopt criteria developed by its CLIA waiver workgroup
CLIAC Reaffirms Quality, Comparability In Waiver Criteria Proposal To HHS
Quality control testing requirements should be included in manufacturer instructions for CLIA-waived assays to compensate for the potential inexperience of lab personnel, the Clinical Laboratory Improvement Advisory Committee (CLIAC) is urging HHS